Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxfendazole is a broad-spectrum benzimidazole anthelmintic primarily used in veterinary medicine to treat and control gastrointestinal parasitism caused by roundworms, strongyles, pinworms, and other helminths in livestock such as cattle, sheep, goats, and horses. It is the sulfoxide metabolite of fenbendazole. Oxfendazole acts by inhibiting microtubule polymerization through binding to β-tubulin in susceptible parasites, disrupting cell division and leading to parasite death. While mainly approved for animal use (notably under brand names like Synanthic), it has shown substantial antiparasitic activity against neurocysticercosis and intestinal helminths in preclinical studies for human use. Clinical development for human indications such as neurocysticercosis and trichuriasis is ongoing[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxfendazole.